Design Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $665.06M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 28, 2026 | During market hours | – | $-0.29 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | During market hours | – | $-0.27 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | During market hours | – | $-0.30 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | – | $-0.31 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | Before market open | – | $-0.24 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | Before market open | – | $-0.21 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | $-0.20 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | During market hours | – | $-0.21 | – |
Press releases
Announcements Design Therapeutics filed with the SEC
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Highlights Progress Across Lead GeneTAC ® Programs and Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Design Therapeutics Highlights Momentum Across Lead GeneTAC ® Programs and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Highlights Progress Across Lead GeneTAC ® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC TM Portfolio
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC TM Portfolio
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results
Results of operations · EX-99.1 to Form 8-K